You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

autologous cell therapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Type 2 Diabetes, Chronic Kidney Disease Trial in United States (Renal Autologous Cell Therapy (REACT®))

Completed
  • Type 2 Diabetes Mellitus
  • Chronic Kidney Disease
  • Renal Autologous Cell Therapy (REACT)
  • Tucson, Arizona
  • +3 more
Jan 6, 2023

A Long-Term Follow-Up Study of Participants Exposed to REACT

Not yet recruiting
  • Diabetic Kidney Disease
  • Chronic Kidney Diseases
  • Renal Autologous Cell Therapy (REACT)
  • (no location specified)
Jun 15, 2023

Type 2 Diabetes, Chronic Kidney Diseases Trial (Renal Autologous Cell Therapy (REACT®))

Not yet recruiting
  • Type 2 Diabetes Mellitus
  • Chronic Kidney Diseases
  • Renal Autologous Cell Therapy (REACT)
  • (no location specified)
Jan 6, 2023

Hepatocellular Carcinoma Trial in Jakarta Pusat (Autologous Natural Killer Cell Therapy, Clinimacs Plus)

Recruiting
  • Hepatocellular Carcinoma
  • Autologous Natural Killer Cell Therapy
  • Clinimacs Plus
  • Jakarta Pusat, Jakarta, Indonesia
    Cipto Mangunkusumo General Hospital
Sep 24, 2023

Degenerative Spine Diseases Trial in Bologna (Vertebral bone marrow (vBMA) clot, Bone allograft chips)

Recruiting
  • Degenerative Spine Diseases
  • Vertebral bone marrow (vBMA) clot
  • Bone allograft chips
  • Bologna, BO, Italy
    Istituto Ortopedico Rizzoli
Jul 14, 2023

ASCT Versus Chemotherapy as First-Line Consolidation Therapy

Completed
  • T-cell Lymphoma Adults
  • consolidation with ASCT
  • (no location specified)
Nov 25, 2023

NK Cell, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory Trial in Hubei (autologous NK cell)

Not yet recruiting
  • NK Cell
  • +2 more
  • autologous NK cell
  • Hubei, Xiangyang, China
    EC of Xiangyang No.1 People's Hospital Hubei University of Medic
Jun 19, 2023

Chronic Kidney Disease, Congenital Anomalies of Kidney and Urinary Tract Trial in United States (Renal Autologous Cell Therapy

Recruiting
  • Chronic Kidney Disease
  • Congenital Anomalies of Kidney and Urinary Tract
  • Renal Autologous Cell Therapy (REACT®)
  • Meridian, Idaho
  • +5 more
Mar 9, 2022

Multiple Myeloma Trial (Iberdomide, Daratumumab/rHuPH20 Co-formulation)

Not yet recruiting
  • Multiple Myeloma
  • (no location specified)
Oct 25, 2023

Lymphomas, B-cell Lymphomas Trial in Houston (JV-213, Leukapheresis)

Not yet recruiting
  • Lymphomas
  • B-cell Lymphomas
  • Houston, Texas
    The University of Texas M D Anderson Cancer Center
Mar 6, 2023

Castration Resistant Prostate Cancer, CRPC Trial in Seoul (Cellgram-DC-PC)

Terminated
  • Castration Resistant Prostate Cancer, CRPC
  • Cellgram-DC-PC
  • Seoul, Korea, Republic of
    Asan medical center
Dec 29, 2022

Hematologic Malignancy, Large B-cell Lymphoma, Acute Lymphoblastic Leukemia Trial in Los Angeles (autologous hematopoietic stem

Not yet recruiting
  • Hematologic Malignancy
  • +5 more
  • autologous hematopoietic stem cells added to planned CAR T
  • Los Angeles, California
    Cedars-Sinai Medical Center
May 31, 2023

Diabetic Kidney Disease, CAKUT, Chronic Kidney Diseases Trial (Renal Autologous Cell Therapy (REACT))

Not yet recruiting
  • Diabetic Kidney Disease
  • +2 more
  • Renal Autologous Cell Therapy (REACT)
  • (no location specified)
Jan 11, 2023

Ovarian Cancer Trial in Seoul (Cellgram-DC)

Terminated
  • Ovarian Cancer
  • Cellgram-DC
  • Seoul, Korea, Republic of
    Asan medical center
Dec 29, 2022

Neuroendocrine Tumor (NET), Colorectal Cancer (CRC) Trial (CHM-2101 CAR-T cells)

Not yet recruiting
  • Neuroendocrine Tumor (NET)
  • Colorectal Cancer (CRC)
  • CHM-2101 CAR-T cells
  • (no location specified)
Sep 20, 2023

Premature Ovarian Failure Trial in Ulaanbaatar (stem cell therapy)

Not yet recruiting
  • Premature Ovarian Failure
  • stem cell therapy
  • Ulaanbaatar, Mongolia
    Mongolian National University of Medical Science
Nov 13, 2023

Multiple Myeloma Trial in Houston (Belantamab mafodotin)

Recruiting
  • Multiple Myeloma
  • Belantamab mafodotin
  • Houston, Texas
    M D Anderson Cancer Center
Jan 5, 2023

Neuroblastoma Trial in Minneapolis (Thiotepa, Cyclophosphamide, Melphalan)

Recruiting
  • Neuroblastoma
  • Minneapolis, Minnesota
    Masonic Cancer Center, University of Minnesota
Nov 2, 2022

Osteoarthritis Trial in Brampton (Bone Marrow Aspirate, Lipoaspirate Concentrate)

Recruiting
  • Osteoarthritis
  • Bone Marrow Aspirate, Lipoaspirate Concentrate
  • Brampton, Ontario, Canada
    Karmy Clinic
Aug 17, 2022

Based on Maintenance Therapy Post Autologous Stem Cell

Recruiting
  • Multiple Myeloma
  • Autologous Stem Cell Transplant
  • +2 more
  • Tampa, Florida
    Moffitt Cancer Center
Jul 27, 2022

Melanoma, NSCLC, Squamous Cell Carcinoma of Head and Neck Trial in United States (GEN-011, IL-2, Fludarabine)

Terminated
  • Melanoma
  • +8 more
  • GEN-011
  • +3 more
  • Gilbert, Arizona
  • +7 more
Jul 13, 2022

Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) Trial (Fludarabine (30 mg/m^2), Cyclophosphamide (500 mg/m^2), CRG-022

Not yet recruiting
  • Cancer
  • Relapsed/Refractory Large B-cell Lymphoma (LBCL)
  • Fludarabine (30 mg/m^2)
  • +2 more
  • (no location specified)
Jul 25, 2023

Urinary Incontinence, Epispadias, Male Trial in Regensburg, Ulm (Primary human muscle stem cells (Satori-01), Placebo)

Not yet recruiting
  • Urinary Incontinence
  • Epispadias, Male
  • Primary human muscle stem cells (Satori-01)
  • Placebo
  • Regensburg, Germany
  • +1 more
Dec 6, 2022

T Cell Lymphoma Trial in Kansas City (Brentuximab Vedotin)

Withdrawn
  • T Cell Lymphoma
  • Brentuximab Vedotin
  • Kansas City, Kansas
    The University of Kansas Cancer Center, Westwood Campus
Feb 1, 2023

Frontline of ASCT in High-risk DLBCL

Recruiting
  • Diffuse Large B Cell Lymphoma
    • Beijing, Beijing, China
      Peking University People's Hospital
    Apr 26, 2023